Loading...
Loading...
Teva Pharmaceutical Industries
TEVA today announced two
significant additions to its global oncology biologic portfolio with the
recent launches of LONQUEX® (lipegfilgrastim) and GRANIX™
(tbo-filgrastim) Injection, and an update on the review status of
balugrastim by the U.S. Food and Drug Administration (FDA).
Teva launched LONQUEX® (long-acting G-CSF) in Germany on November 4,
2013 – the first launch as part of an EU-wide approval. Teva plans to
continue the roll-out of Lonquex across additional countries covered by
the European Marketing Approval over the coming months. Also this month,
Teva launched GRANIX™ (short-acting G-CSF) in the U.S. on November 11,
2013, marking the entry of the first new G-CSF to the US market in more
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in